AOD-9604 vs HGH Fragment 176-191: Are They the Same Peptide?

AOD-9604 vs HGH Fragment 176-191: Are They Different?

Bottom line: These are not two different peptides. AOD-9604 is the pharmaceutical development name assigned by Metabolic Pharmaceuticals. "HGH Fragment 176-191" is a structural descriptor indicating the amino acid positions. Some vendors list both to capture different search queries, and some even sell them as separate SKUs at different prices — but the molecule is identical.

History: How AOD-9604 Was Developed and Why It Failed

In the early 1990s, researchers at Monash University and Metabolic Pharmaceuticals in Melbourne identified that a small fragment of human growth hormone — specifically amino acids 176 through 191 at the C-terminal end — retained the lipolytic (fat-burning) properties of full-length GH without its growth-promoting or diabetogenic effects. This was appealing because it meant a potential fat-loss drug that didn't raise IGF-1 or blood glucose.

The compound was designated AOD-9604 (Anti-Obesity Drug 9604) and entered clinical trials for obesity treatment. Early Phase I and Phase II data showed some promise in reducing body fat. However, the pivotal Phase IIb/III trial (completed around 2007) failed to show statistically significant weight loss compared to placebo over 24 weeks of oral dosing at tested doses.

The development program was effectively abandoned for obesity. The compound later found a second life in osteoarthritis treatment in Australia, where it received TGA approval for intra-articular injection under the brand name iTRAMEL.

Why Vendors Market Them as Different Products

The dual naming persists for several commercial reasons:

• SEO and search capture: "AOD-9604" and "HGH fragment 176-191" are both high-volume search terms. Listing both as separate products doubles a vendor's search visibility.
• Perceived premium: Some vendors price "HGH Fragment 176-191" higher because the name implies a direct connection to human growth hormone — suggesting potency that "AOD-9604" (a dry pharmaceutical code) doesn't evoke.
• Genuine ignorance: Some smaller vendors don't realize they're the same compound. The peptide research chemical market has limited quality control and significant knowledge gaps among resellers.

If you see both listed at different prices from the same vendor, this is a red flag about that vendor's knowledge or integrity.

Does AOD-9604 / HGH Frag Actually Work for Fat Loss?

The honest evidence-based answer is: probably not in a clinically meaningful way.

• The Phase IIb/III obesity trial failed its primary endpoint — oral AOD-9604 did not produce statistically significant weight loss vs. placebo.
• Subcutaneous injection data at higher doses is limited to small, early-phase studies that showed modest fat reduction but were not powered or designed to establish efficacy.
• The peptide's mechanism (stimulating beta-3 adrenergic receptor-mediated lipolysis) is real, but the effect size in humans appears too small to produce meaningful fat loss at tolerable doses.
• Compared to GLP-1 agonists (semaglutide: 15% average body weight loss; tirzepatide: 22%), AOD-9604's signal is negligible.

AOD-9604 remains popular in the research peptide community because of its clean side-effect profile and the intuitive appeal of a "GH fragment that burns fat." But the clinical data does not support it as an effective weight-loss intervention. Users seeking fat loss through peptides are better served by GLP-1 agonists or GH secretagogues (ipamorelin + CJC-1295) that improve body composition through established mechanisms.